Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 8Recurrence 7Neoplasm Metastasis 7Prostatic Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Non-Hodgkin 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Basal Cell 5Multiple Myeloma 4Lymphoma, Follicular 4Hematologic Neoplasms 4Advanced Solid Tumors 4Wilms Tumor 3Solid Tumor 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neuroblastoma 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Itraconazole × Clear all
NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

Phase 1 Active not recruiting
302 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Recruiting
495 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡